Researchers are planning a clinical trial after four metastatic FGFR2 fusion-positive pancreatic cancer patients responded to ...

The agency converted a prior accelerated approval to a traditional approval based on results from the LIBRETTO-531 trial.

The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.

Researchers hope DeepGEM can expedite targeted treatment for lung cancer patients who can't access standard genomic testing.

The Florida-based provider will work with AI software company AiraMed to analyze and measure patients' brain volume from MRIs.

NEW YORK – 858 Therapeutics on Thursday said it raised $50 million in a Series B financing round to advance its pipeline of small molecule therapeutics, including the poly (ADP) ribose glycohydrolase ...

In a report, a working group cautioned that the program must lessen its reliance on congressional appropriations or risk ...

The third-generation EGFR inhibitor will now be an option for patients whose tumors are not metastatic but can't be removed with surgery.

NEW YORK – Bristol Myers Squibb and 2seventy bio said on Wednesday they are discontinuing enrollment in the Phase III KarMMa-9 study evaluating maintenance treatment with CAR T-cel therapy Abecma ...

The ODAC will weigh risk-benefit analyses from the FDA and sponsors on Keytruda, Opdivo, and Tevimbra when given with chemo in all comers and in PD-L1-positive subgroups.

The collaboration will focus on identifying protein biomarkers associated with immunotherapy response across cancer types.

As part of the deal, the companies said they will work together to advance gene therapies for diseases with high unmet medical need.